Century Therapeutics, Inc. (IPSC)
1.86
-0.12
(-6.06%)
USD |
NASDAQ |
Sep 16, 16:00
1.81
-0.05
(-2.69%)
After-Hours: 20:00
Century Therapeutics Enterprise Value : 254.77M for Sept. 16, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 16, 2026 | 254.77M |
| September 15, 2026 | 276.44M |
| September 14, 2026 | 280.05M |
| September 11, 2026 | 269.22M |
| September 10, 2026 | 269.22M |
| September 09, 2026 | 285.47M |
| September 08, 2026 | 292.69M |
| September 04, 2026 | 299.91M |
| September 03, 2026 | 296.30M |
| September 02, 2026 | 299.91M |
| September 01, 2026 | 285.47M |
| August 31, 2026 | 289.08M |
| August 28, 2026 | 284.56M |
| August 27, 2026 | 321.57M |
| August 26, 2026 | 305.33M |
| August 25, 2026 | 310.74M |
| August 24, 2026 | 301.71M |
| August 21, 2026 | 292.69M |
| August 20, 2026 | 283.66M |
| August 19, 2026 | 299.91M |
| August 18, 2026 | 272.83M |
| August 17, 2026 | 271.02M |
| August 14, 2026 | 265.61M |
| August 13, 2026 | 267.41M |
| August 12, 2026 | 272.83M |
| Date | Value |
|---|---|
| August 11, 2026 | 290.88M |
| August 10, 2026 | 276.44M |
| August 07, 2026 | 280.05M |
| August 06, 2026 | 261.99M |
| August 05, 2026 | 272.83M |
| August 04, 2026 | 281.85M |
| August 03, 2026 | 276.44M |
| July 31, 2026 | 283.66M |
| July 30, 2026 | 314.35M |
| July 29, 2026 | 283.66M |
| July 28, 2026 | 289.08M |
| July 27, 2026 | 296.30M |
| July 24, 2026 | 299.91M |
| July 23, 2026 | 310.74M |
| July 22, 2026 | 307.13M |
| July 21, 2026 | 323.38M |
| July 20, 2026 | 314.35M |
| July 17, 2026 | 325.19M |
| July 16, 2026 | 326.99M |
| July 15, 2026 | 310.74M |
| July 14, 2026 | 303.52M |
| July 13, 2026 | 316.16M |
| July 10, 2026 | 325.19M |
| July 09, 2026 | 336.02M |
| July 08, 2026 | 357.68M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Tenax Therapeutics, Inc. | -59.83M |
| Manhattan Scientifics, Inc. | -- |
| Exicure, Inc. | 6.760M |
| Absci Corp. | 1.182B |
| Celularity, Inc. | 105.74M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -34.55M |
| Total Expenses (Quarterly) | 34.55M |
| EPS Diluted (Quarterly) | -0.1679 |
| Earnings Yield | -48.22% |
| Normalized Earnings Yield | -45.96 |